Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEO-CM04S1 vs mRNA Vaccine in Blood Cancer Patients Post-Cellular Therapy
NCT04977024Phase 2Active, not recruiting
- Sponsor
- GeoVax Labs, Inc.
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GEO-CM04S1 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by GeoVax Labs, Inc. Primary endpoint: Biological response. Started Sep 2021; status: active, not recruiting.
02
Drugs
GEO-CM04S1
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04977024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977024.